Loading the session
Loading the session
Loading instrument
$40.85
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:43 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +19.2% (SPY −1.6%, XLV +13.5%). 3 months: −9.3% (SPY −0.4%, XLV +15.5%). 1 year: +147.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: LBRX, SPY and XLV · as of 4 Nov 2026
5.6M shares were sold short at the 15 Oct 2026 settlement; covering them would take 12.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $40.85 was 0.1% below its 50-day average ($40.89) and 24.3% above its 200-day average ($32.86).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $40.85 on 4 Nov 2026: 18.6% below the 52-week high of $50.16 (25 Aug 2026) and 185.3% above the low of $14.32 (11 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
February 5, 2026
+12.71%December 8, 2025
+15.38%November 17, 2025
+14.35%